PharmaTalkRadio

In this podcast, Mike Eckrote, SVP, Strategic Solutions at Advarra, talks about how artificial intelligence is being used to pull insights out of structured and unstructured data sources to help sponsors avoid protocol amendments and delays. More specifically, Mike discusses: How Advarra is leveraging past IRB data sources to identify common causes of site burden, study delays and amendments What questions sponsors should be asking of AI vendors, to pick the correct partner How sponsors have responded to the insights surfaced by this technology Why sponsors must adapt to a flexibility mindset in order to truly make changes with downstream impact

AstraZeneca’s US Site Engagement Leads will share how they are reimagining sponsor-site relationships through a trust-first, high-engagement operating model that emphasizes flexibility, responsiveness, and co-creation. This session will showcase how their embedded approach to collaboration has enabled faster site activation, stronger recruitment performance, and improved data delivery—backed by real metrics and lessons learned from a three-year initiative. Key topics include:How continuous site feedback loops and flexibility with SOPs improved startup timelinesMetrics from a recent study showing impact: 30% faster budget negotiations, 27% reduced activation times, 68% of recruitment from 42% of sitesTools and tactics used to build consistency, transparency, and trust across studiesLessons learned and how the program has scaled globallySpeakers:Shannon Edwards Site Engagement Lead, AstraZenecaTina Nghiem Site Engagement Lead, AstraZeneca

This case study highlights how Basil Clinical Research and Takeda’s first-time partnership became the top global recruiter, exceeding enrollment goals by tenfold through proactive assessments, early collaboration, and inclusive design. Learn how Takeda’s shift from transactional to strategic, long-term partnerships made this success possible.Identifying and partnering with highpotential sitesIncorporating site feedback and early collaboration to improve trial executionBuilding trust and fostering long-term site relationshipsKey actions that led to exceptional enrollment and trial efficiencySpeakers:Brandon Doyle, MBA Associate Director, Study Site Engagement, Takeda Mark Rapp, MD Principal Investigator, Basil Clinical Research

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts address how the biopharma and drug delivery industries actively move to embed sustainability into core principles, products and processes. Specifically:How pharma and suppliers can improve sustainabilityCreating designs with lower carbon footprints relative to fabrication and materialsCircular recycling modelsTo learn more about the PODD Conference, please visit PODDConference.com.

Manufacturing scaleup is a key hurdle in enabling the efficacy of new device technologies. Often this requires a mix of internal and external manufacturing and implementing a commercial control strategy across partners.In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma and CDMO executives discuss effective partnering between pharma and manufacturing as well as growing pains and lessons learned in scaling.To learn more about the PODD Conference, please visit PODDConference.com.

About this Podcast: As pharma sponsors continually assesses how to integrate AI into their ways of working, Evinova’s Chief Technology Officer, Sean Connolly, talks about where, how, and when AI is actually making an impact on clinical development based on insights and experiences of working with pharma.Sean share his thoughts on going for low hanging fruit to encourage adoption, what he's seen in terms of pharma companies that are successfully implementing AI across their enterprise, and how he would recommend organizations that are just starting out on their AI journey assess their individual needs and priorities when it comes to AI.More specifically, Sean discusses: Separating short-term, mid-term and long-term costs and benefits of implementing AI What business leaders at JP Morgan Health 2026 were saying about how they view the value of AI AI deployed for bottom-line revenue versus internal team efficiency What the first steps would be for sponsors to successfully integrate AI across their enterprise

About this podcast:In this keynote from Patients as Partners in Clinical Research 2025, Amicus Therapeutics' Chief Patient Advocate, Jayne Gershkowitz, shares how their organization established and embedded patient advocacy into their core structure for lasting impact.More specifically, Ms Gershkowitz focuses on:Defining role standards and recruiting the right talent Co-creatin research with patient communities and developing patient-centered outcomesGenerating metrics that demonstrate the impact on R&D

Investing in developing a durable platform and strategy early leads to fewer delays throughout development. Locking requirements in early and educating teams to approach combination product development holistically lowers the time to development dramatically. In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss how they used platform devices in concert with an internal engagement strategy to speed up development. Specifically, they address: Advantages and disadvantages to platform approaches for device developmentOpportunities to overcome technical limitationsApproaches to bring a platform into multiple product design history filesRegulatory hurdlesAssessing business case and getting organizational buy-inTo learn more about the PODD Conference, please visit Drug-Delivery.org.

About this podcast: Recorded at the 2025 IO360º Summit, this podcast addresses how Project Optimus is reshaping dose selection from maximum tolerated dose to a balance of efficacy and safety. More specifically, this panel addresses FDA objectives for multi-dose selection, alternative dose-selection strategies with imaging, biomarkers and tumor burden analysis, the higher costs and longer timelines, and financial impacts for early-phase oncology companies. For more information, go to IO360summit.com.

About this podcast:This podcast, recorded at the 2025 Patients as Partners Europe meeting, addresses how Novo Nordisk is consolidating patient insights to ensure greater knowledge-sharing, data integrity and traceability, addressing the unmet needs of patients, aligning product outcomes with patient expectations, and more. For more information, go to theconferenceforum.org.

In this podcast, featuring a panel discussion from the 2025 Chief Medical Officer Summit 360°, CMOs with recent M&A and partnership experience share those experiences as well as how CMOs of other small to midsize emerging biotech companies can support the conversations and operations that take place throughout the process of business development. Specifically:Different kinds of BD deals to be aware ofHow the CMO fits into various phases of transactionsAppreciating how different c-suite colleagues and direct reports experience these transactionsThe different pharma teams CMOs will interact withWhat happens after the acquisitionTo learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.

This podcast features a panel discussion from the 2025 Chief Medical Officer Summit 360° about how to strategically approach hiring FTEs, insourcing, outsourcing and contracting to be appropriately prepared for the different stages of a biotech companies development from preclinical to early stage to late stage trials to commercialization. Specifically:Balancing the mix of hires and outsourcingHiring for skillsets to enable efficiency without overhiringReactive vs proactive hiringBuilding in a stage appropriate way but also hiring in time for later stagesTo learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.

About this podcast: This podcast comes from the DPHARM 2025 meeting. Pfizer details how they jointly co-designed and implemented an EDC/CDMS platform that’s fit for purpose, and analysis data set. This session focuses on:Engaging all stakeholders in designing the platformThe evolution of the platform focus: the transition from the majority of data coming from EDC to 3/4 of the data from third party sourcesImpact of the advanced data analysis capabilities for risk managementReview of impact on initial studies now using the platform For more information, go to DPHARMconference.com.